Nadjiri Jonathan, Geith Tobias, Mühlmann Marc, Waggershauser Tobias, Paprottka Philipp M
Department of Interventional Radiology, School of medicine, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, DE, Germany.
CVIR Endovasc. 2023 Feb 16;6(1):6. doi: 10.1186/s42155-023-00350-5.
Besides other factors, complication rate of transarterial interventions depends on the size of the vascular access. Therefore, the vascular access is mostly chosen as small as possible while still allowing all planned parts of the intervention. This retrospective analysis is to evaluate the safety and feasibility of sheathless arterial interventions for a broad spectrum of interventions in daily practice.
All sheathless interventions using a 4 F main catheter between May 2018 and September 2021 were included in the evaluation. Additionally, intervention parameters such as type of catheter, use of microcatheter and required change of main catheters were assessed. Information about the use about sheathless approach and catheters were obtained from the material registration system. All catheters were braided.
503 sheathless interventions with 4 F catheters from the groin were documented. The spectrum comprised bleeding embolization, diagnostic angiographies, arterial DOTA-TATE-therapy, uterine fibroid embolization, transarterial chemotherapy, transarterial radioembolization and others. In 31 cases (6 %) a change of the main catheter was required. In 381 cases (76 %) a microcatheter was utilized. No clinically relevant adverse events were observed (grade 2 or higher [CIRSE AE-classification]). None of the cases later required conversion to a sheath-based intervention.
Sheathless interventions with a 4 F braided catheter from the groin are safe and feasible. It allows for a broad spectrum of interventions in daily practice.
除其他因素外,经动脉介入治疗的并发症发生率取决于血管通路的大小。因此,在仍能进行所有计划中的介入治疗部分的情况下,血管通路大多选择尽可能小。本回顾性分析旨在评估在日常实践中,无鞘动脉介入治疗对广泛的介入治疗的安全性和可行性。
评估2018年5月至2021年9月期间所有使用4F主导管的无鞘介入治疗。此外,还评估了介入参数,如导管类型、微导管的使用以及主导管所需的更换情况。关于无鞘方法和导管使用的信息从材料登记系统中获取。所有导管均为编织型。
记录了503例经腹股沟使用4F导管的无鞘介入治疗。治疗范围包括出血栓塞、诊断性血管造影、动脉DOTA-TATE治疗、子宫肌瘤栓塞、经动脉化疗、经动脉放射性栓塞等。31例(6%)需要更换主导管。381例(76%)使用了微导管。未观察到临床相关不良事件(2级或更高[CIRSE不良事件分类])。所有病例后期均无需转换为基于鞘管的介入治疗。
经腹股沟使用4F编织导管进行无鞘介入治疗是安全可行的。它在日常实践中允许进行广泛的介入治疗。